NIH PAR · NINDS · UG3, UH3
PAR-25-052: NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement…
- NOFO number
- PAR-25-052
- Type
- PAR
- Activity code
- UG3UH3
- Primary institute
- NINDS · National Institute of Neurological Disorders and Stroke
- Clinical trials
- Optional
- Posted
- Nov 20, 2024
- Opens
- Jan 18, 2025
- Expires
- Nov 20, 2026
PAR-25-052 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 19, 2025 | March 19, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 20, 2025 | July 18, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 20, 2025 | November 19, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 19, 2026 | March 16, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 18, 2026 | July 20, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 19, 2026 | November 19, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-052
NIH RePORTER lists 1 project funded under PAR-25-052 in FY2022–FY2026, with $2.6M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$2.6M
Award dollars under PAR-25-052, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 1 | 1 | $2.6M |
Institutions with the most funding
- Cedars-Sinai Medical Center$2.6M · 1 project
Funding institutes
- NINDS$2.6M · 1
Activity codes funded
- UG31 record
Most recent new awards
- ERSIAS Phase IIb EDAS Revascularization for Symptomatic Intracranial Atherosclerotic Steno occlusive Disease Phase IIb Clinical Trial (opens NIH RePORTER)
Cedars-Sinai Medical Center · 1UG3NS150909-01 · NINDS · Notice Sep 17, 2026
$2.6MUG3
What its predecessor PAR-24-101 funded
PAR-25-052 reissues PAR-24-101. Its funding history is the best guide to who wins under this program: 3 projects and $11.7M in FY2022–FY2026.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$11.7M
Award dollars under PAR-24-101, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 2 | 2 | $8.1M |
| FY2026 | 1 | 0 | $3.7M |
Institutions with the most funding
- Stanford University$5.7M · 1 project
- Weill Medical Coll of Cornell Univ$3.7M · 1 project
- Icahn School of Medicine at Mount Sinai$2.3M · 1 project
Funding institutes
- NINDS$11.7M · 3
Activity codes funded
- UG32 records
- UH31 record
Most recent new awards
- Cilostazol for Prevention of Recurrent Stroke (CLARITY) (opens NIH RePORTER)
Stanford University · 1UG3NS133209-01A1 · NINDS · Notice Aug 13, 2025
$5.7MUG3
- Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1UG3NS138638-01A1 · NINDS · Notice Aug 1, 2025
$2.3MUG3
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-052. Contact the program officer at the institute that fits your research before applying.
- NINDS · National Institute of Neurological Disorders and Stroke
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the requested project award period. The project period for the UG3 phase will be up to 1 year. The project period for the UH3 phase is expected to be 4 years. With strong justification, up to 6 years for the UH3 may be requested.  NIH grants policies as described in the NIH Grants Policy Statement will apply to the…
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-101.
Other open NOFOs for UG3, UH3
- RFA-NS-27-007HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 21, 2026
- PAR-27-065NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)NINDS · next due Nov 9, 2026
- PAR-24-293Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)NINDS · next due Jan 15, 2027
- PAR-25-383Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)NINDS · next due Jan 28, 2027
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.